4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) operates in the Biotechnology industry and is headquartered in Wuhan, China with about 55 employees. Its market capitalization is roughly HKD 4 billion. In the fiscal year ended 2025-12-31, 3378 reported HKD 0M in revenue and (HKD 131M) in net income.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | HKD 0M | HKD 0M | HKD 0M |
| Operating Income (EBIT) | (HKD 150M) | (HKD 119M) | (HKD 61M) |
| Net Income | (HKD 131M) | (HKD 116M) | (HKD 76M) |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | HKD 936M | HKD 502M | HKD 586M |
| Total Liabilities | HKD 188M | HKD 285M | HKD 267M |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 3378 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms